Micromet, Serono amend adecatumumab deal

MITI and Serono (SWX:SEO; SRA) amended a 2004 deal to develop adecatumumab ( MT201). Under the amended

Read the full 174 word article

User Sign In

Article Purchase

This article may not be distributed to non-subscribers

PURCHASE THIS ARTICLE FOR LIMITED ONE-TIME DISTRIBUTION AND WEBSITE POSTING $995.00 USD

PURCHASE